CA Solís Olivares, C Jerjes-Sánchez Díaz, T Archondo Arce

Language: Spanish
References: 21
Page: 197-204
PDF size: 79.38 Kb.

ABSTRACT

Background: Our current knowledge on the prognosis of systolic left ventricular dysfunction has been obtained through multicentric trials performed at third level health care institutions, which usually include patients based on strict inclusion criteria. Objective: To establish in systolic left ventricular dysfunction patients, evaluated at a community hospital, a risk profile for adverse cardiovascular events and to know their survival. Methods: Prospective study with 4 years follow-up. Inclusion criteria: a) Symptomatic patients with systolic left ventricular dysfunction, b) any NYHA functional class or etiology, c) ejection fraction < 40%. Exclusion criteria: a) Asymptomatic patients, b) acute coronary syndrome in the last 6 weeks, c) ventricular dysfunction secondary to pulmonary arterial hypertension, d) severe systemic illness or neoplasms causing disability < 6 months. Statistics: Student’s t test, Chi-square, Yates and Mantel-Haenszel. Unvariant and multivariant logistic regression analysis. Cox and Kaplan-Meier method. Significance was set at p < 0.05. Results: From January 1997 to January 2001, 110 patients were studied, 61% men and 39% women, their age were 61± 13.1 years. Ischemic etiology in 46% and 54%, 68% in III/IV NYHA class and 32% in I/II NYHA class. Basal left ventricular ejection fraction was 28 ± 6.9%. Patients were followed for 30.11 ± 18.7 months, with 26% of global mortality. Through lineal, logistic and multivariate regression analysis, the high clinical risk profile was identified, corresponding > 65 years, female gender, hypertension, diabetes mellitus II, ischemic heart disease, III/IV NYHA class and ventricular tachycardia (p = 0.00001). Conclusion: In the "real world" of systolic left ventricular dysfunction, the identified risk profile allows stratify high priority subgroup of patients to be enrolled in a cardiac transplant program.

REFERENCES

1. Eriksson H: Heart failure: a growing public health problem. J Intern Med 1995; 237: 135-141.

2. De Teresa E, Alsueta J, Jimenez-Navarro M: Profiling risk from arrhythmic or hemodynamic death. Am J Cardiol 2000; 86: 126k-132k.

3. Gibbons JR, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, et al: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001; 38: 2101-13.

4. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. W.J. Remme and K. Swedberg (Co-chairmen): Guidelines for the diagnosis and treatment of Chronic Heart Failure. Eur Heart J 2001; 22: 1527-1560.

5. Massie BM, Shah NB: Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997; 133(6): 703-712.

6. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-1435.

7. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999; 353: 9-13.

8. Pitt B, Segal R, Martinez FA, Meurer G, Cowley A, Thomas I, et al: Randomized trial of losartan versus captopril in patient over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.

9. Almenar L, Morillas P, Rueda J, Roldán FJ, Osa Ana, Palencia M: Evaluación de los candidatos a trasplante cardíaco. Indicaciones, pronóstico y selección de pacientes. Arch Inst Cardiol Mex 2000; 70: 407-416.

10. Urestky BF, Sheahan RG: Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol 1997; 30: 1589-1597.

11. Anguita M, Torres F, Valles F: Marcadores de la actuación clínica en pacientes con miocardiopatía dilatada. Rev Esp Cardiol 1996; 49: 689-692.

12. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, Dibianco R, Zeldis SM, et al: Effect of milrinone on mortality in severe heart failure. N Engl J Med 1991; 325: 1468-1475.

13. Keogh AM, Baron DW, Hickie JB: Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for heart transplantation. Am J Cardiol 1990; 65: 903-908.

14. Stevenson WG, Stevenson LW, Middlekauff HR, Fonarow GC, Hamilton MA, Woo MA, et al: Improving survival with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol 1995; 26: 1417-1423.

15. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R: Randomized trial of low dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493-498.

16. Anguita M, Arizon J, Bueno G, Latre J, Sancho M, Torres F, et al: Clinical and hemodynamic predictors of survival in patients aged < 65 years with severe congestive failure secondary to ischemic or no ischemic dilated cardiomyopathy. Am J Cardiol 1993; 72: 413-417.

17. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure. N Engl J Med 1995; 333: 77-82.

18. Gradman A, Deedwania P, Cody R, Massie B, Packer M, Pitt B, et al: Predictors of total mortality and sudden death in mild to moderate heart failure. J Am Coll Cardiol 1989; 14: 564-570.

19. Yan AT, Bradley D, Liu PP: The role of continuous positive airway pressure in the treatment of congestive heart failure. Chest 2001; 120: 1675-1685.

20. Stafford RS, Saglam D, Blumenthal D: National patterns of angiotensin-converting enzyme inhibitor us in congestive heart failure. Arch Intern Med 1997; 157: 2460-2464.

21. Young JB, Gheorghiade M, Uretski BF, Patterson JH, Adams KF: Superiority of “triple” drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective randomized study of ventricular function and efficacy of digoxin. Randomized assessment of digoxin and inhibitor of angiotensin-converting enzyme. J Am Coll Cardiol 1998; 32: 686-692.